₹37.3
Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | + 27.83 % |
3 Month Return | + 29.18 % |
1 Year Return | + 26.21 % |
Market Stats | |
Previous Close | ₹37.85 |
Open | ₹38.98 |
Volume | 2,066.00 |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹14.16Cr |
P/E Ratio | 0 |
PEG Ratio | 0 |
Market Cap | ₹14.16 Cr |
P/B Ratio | 2.31 |
EPS | 0 |
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
![]() | NA | ₹14.16 Cr | 21.71% | 0.74 | NA | NA |
![]() | NA | ₹17.18 Cr | -6.84% | 0.50 | -₹3 Cr | ₹45 Cr |
![]() | NA | ₹164.28 Cr | 90.19% | 0.58 | NA | NA |
![]() | NA | ₹1,131.02 Cr | 120.9% | 0.54 | ₹27 Cr | ₹550 Cr |
![]() | NA | ₹14.76 Cr | 80.9% | 0.69 | NA | NA |
Organisation | Parmax Pharma Ltd |
Headquarters | |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Key events for Parmax Pharma Ltd
Parmax Pharma's standalone net sales for March 2024 stood at Rs 4.26 crore, down 33.29% YoY. The company reported a loss of Rs 1.45 crore in the same period.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Retail Holding Up
Retail Investor have increased holdings from 69.17% to 69.20% in Jun 2024 quarter
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 127.7% return, outperforming this stock by 154.1%
Against Peers
In the last 1 year, Zydus Lifesciences Ltd has given 87.2% return, outperforming this stock by 61.0%
Promoter Holding Down
Promoters have decreased holdings from 30.83% to 30.80% in Jun 2024 quarter
Price Dip
In the last 7 days, Parmax Pharma stock has moved down by -12.2%
2023 | Y/Y Change | |
---|---|---|
Total Assets | ₹17.60Cr | ↓2.06% |
Total Liabilities | ₹11.75Cr | ↓2.16% |
2023 | Y/Y Change | |
---|---|---|
Operating Cash Flow | ₹0.33Cr | ↓56.00% |
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 30.8% | ||
Foreign Institutions | 0% | 0.00 | |
Mutual Funds | 0% | 0.00 | |
Retail Investors | 69.2% | 0.04 | |
Others | 0% | 0.00 |
Parmax Pharma Ltd’s net profit fell -952.94% since last year same period to ₹-1.45Cr in the Q4 2023-2024. On a quarterly growth basis, Parmax Pharma Ltd has generated 17.14% jump in its net profits since last 3-months.
Read More about Earnings ResultsBearish
Neutral
Bullish
Parmax Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.
Parmax Pharma Ltd (540359) share price today is ₹37.3
Parmax Pharma Ltd is not listed on NSE
Parmax Pharma Ltd is listed on BSE
Today’s traded volume of Parmax Pharma Ltd(540359) is 2,066.00.
Today’s market capitalisation of Parmax Pharma Ltd(540359) is ₹14.16Cr.
Parmax Pharma Ltd(540359 | Price |
---|---|
52 Week High | ₹47.77 |
52 Week Low | ₹24.18 |
Parmax Pharma Ltd(540359) share price is ₹37.3. It is down -21.92% from its 52 Week High price of ₹47.77
Parmax Pharma Ltd(540359) share price is ₹37.3. It is up 54.26% from its 52 Week Low price of ₹24.18
Parmax Pharma Ltd(540359 | Returns |
---|---|
1 Day Returns | -0.55% |
1 Month Returns | 27.83% |
3 Month Returns | 29.18% |
1 Year Returns | 26.21% |